Foghorn Therapeutics (FHTX) Liabilities and Shareholders Equity (2019 - 2026)

Foghorn Therapeutics' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $222.2 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 14.12% year-over-year to $222.2 million in Q1 2026; TTM through Mar 2026 was $851.5 million, a 27.82% decrease from a year earlier, with the FY2025 full-year figure at $198.1 million, down 30.24% from the prior year.
• Liabilities and Shareholders Equity climbed to $222.2 million in Q1 2026 per FHTX's latest filing, from $198.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $488.3 million in Q1 2022 and bottomed at $198.1 million in Q4 2025.
• The 5-year median for Liabilities and Shareholders Equity is $308.4 million (2024), against an average of $316.6 million.
• Across the five-year window, Liabilities and Shareholders Equity soared 133.21% in 2022 and sank 33.53% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $404.9 million in 2022, then fell by 29.38% to $285.9 million in 2023, then declined by 0.68% to $284.0 million in 2024, then tumbled by 30.24% to $198.1 million in 2025, then rose by 12.15% to $222.2 million in 2026.
• Per Business Quant, the three latest FHTX Liabilities and Shareholders Equity figures stand at $222.2 million (Q1 2026), $198.1 million (Q4 2025), and $205.0 million (Q3 2025).